Drugs / JAB-3068
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03518554 | Apr 2018 → Feb 2022 | esophageal cancer, head and neck cancer, metastatic neoplasm, non-small cell lung carcinoma | Jacobio Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04721223 | Apr 2021 → Dec 2023 | esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma | Jacobio Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03565003 | Nov 2018 → Jan 2023 | esophageal cancer, head and neck cancer, metastatic neoplasm, non-small cell lung carcinoma | Jacobio Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JAB-3068 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03565003 ↗ |
| Action | Inhibit | “JAB-3068 (SHP2 inhibitor)” NCT03518554 ↗ |
| Modality | Small molecule | — CHEMBL5095185 ↗ |
| Route | Oral | “JAB-3068 will be orally administered on a daily basis.” NCT03518554 ↗ |